RYTM
Income statement / Annual
Last year (2025), Rhythm Pharmaceuticals Inc.'s total revenue was $189.76 M,
an increase of 45.83% from the previous year.
In 2025, Rhythm Pharmaceuticals Inc.'s net income was -$196.54 M.
See Rhythm Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$189.76 M |
$130.13 M |
$77.43 M |
$23.64 M |
$3.15 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$19.49 M
|
$13.37 M
|
$9.30 M
|
$2.13 M
|
$599.00 K
|
$690.00 K
|
$834.00 K
|
$442.00 K
|
$223.00 K
|
$144.00 K
|
| Gross Profit |
$170.27 M
|
$116.76 M
|
$68.13 M
|
$21.51 M
|
$2.56 M
|
-$690.00 K
|
-$834.00 K
|
-$442.00 K
|
-$223.00 K
|
-$144.00 K
|
| Gross Profit Ratio |
0.9
|
0.9
|
0.88
|
0.91
|
0.81
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$167.34 M
|
$237.96 M
|
$134.95 M
|
$108.63 M
|
$104.13 M
|
$90.45 M
|
$109.45 M
|
$50.34 M
|
$22.89 M
|
$19.59 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.08 M
|
$9.52 M
|
$6.31 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$194.94 M
|
$144.30 M
|
$117.53 M
|
$92.03 M
|
$68.49 M
|
$46.13 M
|
$36.55 M
|
$28.08 M
|
$9.52 M
|
$6.31 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$690.00 K
|
-$834.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$362.28 M
|
$382.26 M
|
$252.48 M
|
$200.66 M
|
$172.61 M
|
$135.89 M
|
$145.17 M
|
$78.42 M
|
$32.41 M
|
$25.91 M
|
| Cost And Expenses |
$381.77 M
|
$395.63 M
|
$261.79 M
|
$202.80 M
|
$173.21 M
|
$136.58 M
|
$146.00 M
|
$78.42 M
|
$32.41 M
|
$25.91 M
|
| Interest Income |
$15.29 M
|
$14.71 M
|
$13.95 M
|
$4.03 M
|
$447.00 K
|
$2.58 M
|
$5.27 M
|
$4.35 M
|
$566.00 K
|
$33.00 K
|
| Interest Expense |
$20.58 M
|
$20.60 M
|
$13.89 M
|
$5.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.34 M
|
$1.56 M
|
$1.76 M
|
$1.67 M
|
$1.16 M
|
$690.00 K
|
$834.00 K
|
$442.00 K
|
$223.00 K
|
$144.00 K
|
| EBITDA |
-$174.12 M |
-$238.09 M |
-$168.46 M |
-$174.25 M |
-$68.45 M |
-$135.89 M |
-$145.17 M |
-$77.98 M |
-$32.19 M |
-$25.76 M |
| EBITDA Ratio |
-0.92
|
-1.83
|
-2.18
|
-7.37
|
-21.7
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.01
|
-2.04
|
-2.38
|
-7.58
|
-53.92
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.03 M
|
$5.25 M
|
$243.00 K
|
-$1.96 M
|
$100.45 M
|
$2.58 M
|
$5.27 M
|
$4.35 M
|
-$1.30 M
|
$33.00 K
|
| Income Before Tax |
-$196.04 M
|
-$260.26 M
|
-$184.11 M
|
-$181.12 M
|
-$69.61 M
|
-$134.00 M
|
-$140.73 M
|
-$74.06 M
|
-$33.71 M
|
-$25.87 M
|
| Income Before Tax Ratio |
-1.03
|
-2
|
-2.38
|
-7.66
|
-22.07
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$497.00 K
|
$346.00 K
|
$564.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$196.54 M
|
-$260.60 M
|
-$184.68 M
|
-$181.12 M
|
-$69.61 M
|
-$130.73 M
|
-$134.62 M
|
-$74.06 M
|
-$33.71 M
|
-$25.87 M
|
| Net Income Ratio |
-1.04
|
-2
|
-2.39
|
-7.66
|
-22.07
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.11 |
-4.34 |
-3.2 |
-3.51 |
-1.37 |
-2.96 |
-3.7 |
-2.39 |
-1.26 |
-1.55 |
| EPS Diluted |
-3.11 |
-4.34 |
-3.2 |
-3.51 |
-1.37 |
-2.96 |
-3.7 |
-2.39 |
-1.26 |
-1.55 |
| Weighted Average Shares Out |
$64.98 M
|
$61.00 M
|
$57.67 M
|
$52.12 M
|
$49.60 M
|
$44.13 M
|
$36.42 M
|
$31.00 M
|
$26.73 M
|
$16.73 M
|
| Weighted Average Shares Out Diluted |
$64.98 M
|
$61.00 M
|
$57.67 M
|
$52.12 M
|
$49.60 M
|
$44.13 M
|
$36.42 M
|
$31.00 M
|
$26.73 M
|
$16.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
